We are live on ! Find out more
PSC

Patient Square Capital Portfolio holdings

AUM $646M
1-Year Est. Return 291.07%
This Fund
S&P 500
This Quarter Est. Return
+24.89%
1 Year Est. Return
+291.07%
3 Year Est. Return
+328.76%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$646M
AUM Growth
+$81.9M
Cap. Flow
-$14.5M
Cap. Flow %
-2.25%
Top 10 Hldgs %
80.13%
Holding
35
New
6
Increased
9
Reduced
8
Closed
12

Top Buys

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$40.3M
2
UTHR icon
United Therapeutics
UTHR
+$20.9M
3
BNTX icon
BioNTech
BNTX
+$12.7M
4
ABVX
Abivax
ABVX
+$9.65M
5
IVA
Inventiva
IVA
+$9.45M

Top Sells

Rank Stock Value
1
INSM icon
Insmed
INSM
+$25.8M
2
LEGN icon
Legend Biotech
LEGN
+$17.9M
3
NKTR icon
Nektar Therapeutics
NKTR
+$15.1M
4
ARGX icon
argenx
ARGX
+$11.3M
5
CELC icon
Celcuity
CELC
+$10.8M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ROIV icon
1
Roivant Sciences
ROIV
$28.9B
$284M 43.97%
8,020,928
-145,119
-2% -$4.29M
RVMD icon
2
Revolution Medicines
RVMD
$42.2B
$51.7M 8.01%
+276,000
New +$40.3M
MIRM icon
3
Mirum Pharmaceuticals
MIRM
$6.42B
$30.5M 4.72%
260,500
+30,500
+13% +$3.06M
ABVX
4
Abivax
ABVX
$9.34B
$27.5M 4.26%
206,500
+85,255
+70% +$9.65M
ONC
5
BeOne Medicines Ltd
ONC
$40B
$25.7M 3.97%
90,020
+9,478
+12% +$2.79M
PHVS icon
6
Pharvaris
PHVS
$2.67B
$23.2M 3.6%
671,209
+178,209
+36% +$5.39M
ARGX icon
7
argenx
ARGX
$62.3B
$21.3M 3.31%
23,000
-13,718
-37% -$11.3M
UTHR icon
8
United Therapeutics
UTHR
$21.3B
$20.1M 3.12%
+37,120
New +$20.9M
BLTE
9
Belite Bio
BLTE
$6.86B
$16.9M 2.62%
110,000
-6,684
-6% -$1.02M
COGT icon
10
Cogent Biosciences
COGT
$5.76B
$16.4M 2.55%
425,000
-171,000
-29% -$5.98M
DBVT
11
DBV Technologies S.A. American Depositary Shares
DBVT
$786M
$14.9M 2.31%
909,474
+215,940
+31% +$4.07M
XENE icon
12
Xenon Pharmaceuticals
XENE
$5.55B
$13.3M 2.06%
220,000
-7,000
-3% -$389K
BNTX icon
13
BioNTech
BNTX
$24.8B
$12.5M 1.94%
+134,429
New +$12.7M
RCUS icon
14
Arcus Biosciences
RCUS
$3.25B
$11M 1.7%
355,800
+160,800
+82% +$3.97M
ELVN icon
15
Enliven Therapeutics
ELVN
$3.68B
$10.8M 1.67%
212,500
+12,500
+6% +$531K
DNTH icon
16
Dianthus Therapeutics
DNTH
$5.66B
$10.5M 1.63%
108,000
+14,118
+15% +$1.23M
ALLO icon
17
Allogene Therapeutics
ALLO
$598M
$10.5M 1.63%
5,050,000
+1,600,000
+46% +$3.51M
EYPT icon
18
EyePoint Inc
EYPT
$344M
$10.3M 1.6%
720,000
-75,000
-9% -$1M
ARQT icon
19
Arcutis Biotherapeutics
ARQT
$3.33B
$9.7M 1.5%
370,000
-30,645
-8% -$714K
CCCC icon
20
C4 Therapeutics
CCCC
$420M
$7.51M 1.16%
+1,608,815
New +$5.5M
IVA
21
Inventiva
IVA
$886M
$7.44M 1.15%
+1,967,171
New +$9.45M
KYMR icon
22
Kymera Therapeutics
KYMR
$9.85B
$5.45M 0.84%
47,500
-52,500
-53% -$4.51M
FTH
23
Faeth Therapeutics
FTH
$908M
$4.38M 0.68%
+175,050
New +$4.05M
ASMB icon
24
Assembly Biosciences
ASMB
$516M
– –
-136,315
Closed -$3.78M
CATX icon
25
Perspective Therapeutics
CATX
$329M
– –
-1,625,000
Closed -$6.78M
1
2

Similar funds

WW
Waterfront Wealth Overland Park, Kansas $645M AUM 27.59% 1-Year Est. Return
AP
Advisors Preferred Rockville, Maryland $646M AUM 32.22% 1-Year Est. Return
LFS
Legacy Financial Strategies Overland Park, Kansas $646M AUM 23.5% 1-Year Est. Return
CAMV
Concord Asset Management (Virginia) Abingdon, Virginia $646M AUM 25.36% 1-Year Est. Return
BCB
Brian C. Broderick $646M AUM 43.3% 1-Year Est. Return
ML
Mayport LLC Newton, Massachusetts $645M AUM 19.45% 1-Year Est. Return
JCP
JB Capital Partners Armonk, New York $646M AUM 39.9% 1-Year Est. Return
HIS
Harvest Investment Services Oakbrook Terrace, Illinois $647M AUM 89.3% 1-Year Est. Return

Patient Square Capital's Q2 2026 Portfolio in Review

As of Q2 2026, Patient Square Capital held 35 positions worth $646M, up 15% from $564M the previous quarter. Its ten largest holdings account for 80% of the portfolio.

Patient Square Capital's Q2 2026 filing shows 6 new, 9 increased, 8 reduced and 12 closed positions. Its largest new stake was Revolution Medicines: 276,000 shares worth $51.7M. The largest sale was Insmed, an estimated $25.8M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Patient Square Capital's largest Q2 2026 buy was Revolution Medicines: 276,000 shares worth $51.7M.
  • Patient Square Capital added most to Abivax in Q2 2026, an estimated $9.65M increase.
  • Patient Square Capital's biggest Q2 2026 reduction was argenx, cutting an estimated $11.3M.
  • Patient Square Capital fully exited Insmed in Q2 2026, selling an estimated $25.8M.
  • Patient Square Capital's ten largest holdings make up 80% of its $646M portfolio in Q2 2026.
  • Patient Square Capital opened 6 new positions and closed 12 in Q2 2026.
  • Patient Square Capital's portfolio value rose 15% quarter-over-quarter to $646M.

Based on Patient Square Capital's 13F filing for Q2 2026, filed 12 Aug 2026.